Effective protection against secondary pneumococcal pneumonia by oral vaccination with attenuated Salmonella delivering PspA antigen in mice

Vaccine

Volumn 30, Issue 48, 2012, Pages 6816-6823

  Seo, Sang Uk ^a   Kim, Jae Jin ^a   Yang, Hyungjun ^a   Kwon, Hyung Joon ^a   Yang, Jin Young ^a   Curtiss, Roy ^b   Kweon, Mi Na ^a  

^a International Vaccine Institute   (South Korea)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Influenza infection; Mucosal vaccine; Pneumonia; Secondary pneumococcal infection; Streptococcus pneumoniae

Indexed keywords

CD11B ANTIGEN; CHEMOKINE RECEPTOR CCR2; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; OSELTAMIVIR; PNEUMOCOCCAL SURFACE PROTEIN A; PNEUMOCOCCUS VACCINE; SALMONELLOSIS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL INFECTION; BODY WEIGHT; CELL INFILTRATION; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; HISTOPATHOLOGY; IMMUNE RESPONSE; INFECTION PREVENTION; INFLAMMATION; INFLUENZA; LONG TERM CARE; LUNG ALVEOLITIS; LUNG ALVEOLUS EPITHELIUM; LUNG LAVAGE; MOUSE; NEUTROPHIL; NONHUMAN; PASSIVE IMMUNIZATION; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIA; TH2 CELL; TREATMENT DURATION; VACCINATION; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; BACTERIAL PROTEINS; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; SALMONELLA VACCINES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 84868192126     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.015     Document Type: Article

References (40)

1. Chien Y.W., Klugman K.P., Morens D.M. Bacterial pathogens and death during the 1918 influenza pandemic. N Engl J Med 2009, 361(26):2582-2583.
2. Morens D.M., Taubenberger J.K., Fauci A.S. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008, 198(7):962-970.
3. Estenssoro E., Rios F.G., Apezteguia C., Reina R., Neira J., Ceraso D.H., et al. Pandemic 2009 influenza A in Argentina: a study of 337 patients on mechanical ventilation. Am J Respir Crit Care Med 2010, 182(1):41-48.
4. Madhi S.A., Klugman K.P. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004, 10(8):811-813.
5. Gonzalez-Fernandez A., Faro J., Fernandez C. Immune responses to polysaccharides: lessons from humans and mice. Vaccine 2008, 26(3):292-300.
6. Arulanandam B.P., Lynch J.M., Briles D.E., Hollingshead S., Metzger D.W. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun 2001, 69(11):6718-6724.
7. Ferreira D.M., Darrieux M., Silva D.A., Leite L.C., Ferreira J.M., Ho P.L., et al. Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice. Clin Vaccine Immunol 2009, 16(5):636-645.
8. Ogunniyi A.D., Woodrow M.C., Poolman J.T., Paton J.C. Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect Immun 2001, 69(10):5997-6003.
9. Ren B., Szalai A.J., Thomas O., Hollingshead S.K., Briles D.E. Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect Immun 2003, 71(1):75-85.
10. Shaper M., Hollingshead S.K., Benjamin W.H., Briles D.E. PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin. Infect Immun 2004, 72(9):5031-5040.
11. Ezoe H., Akeda Y., Piao Z., Aoshi T., Koyama S., Tanimoto T., et al. Intranasal vaccination with pneumococcal surface protein A plus poly(I:C) protects against secondary pneumococcal pneumonia in mice. Vaccine 2011, 29(9):1754-1761.
12. King Q.O., Lei B., Harmsen A.G. Pneumococcal surface protein A contributes to secondary Streptococcus pneumoniae infection after influenza virus infection. J Infect Dis 2009, 200(4):537-545.
13. Kang H.Y., Srinivasan J., Curtiss R. Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccine. Infect Immun 2002, 70(4):1739-1749.
14. Park S.M., Ko H.J., Shim D.H., Yang J.Y., Park Y.H., Curtiss R., et al. MyD88 signaling is not essential for induction of antigen-specific B cell responses but is indispensable for protection against Streptococcus pneumoniae infection following oral vaccination with attenuated Salmonella expressing PspA antigen. J Immunol 2008, 181(9):6447-6455.
15. Winter C., Herbold W., Maus R., Langer F., Briles D.E., Paton J.C., et al. Important role for CC chemokine ligand 2-dependent lung mononuclear phagocyte recruitment to inhibit sepsis in mice infected with Streptococcus pneumoniae. J Immunol 2009, 182(8):4931-4937.
16. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005, 353(13):1363-1373.
17. Fedson D.S., Scott J.A. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 1999, 17(Suppl 1):S11-S18.
18. Artz A.S., Ershler W.B., Longo D.L. Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev 2003, 16(2):308-318.
19. Lieu T.A., Ray G.T., Black S.B., Butler J.C., Klein J.O., Breiman R.F., et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 2000, 283(11):1460-1468.
20. Samore M.H., Magill M.K., Alder S.C., Severina E., Morrison-De Boer L., Lyon J.L., et al. High rates of multiple antibiotic resistance in Streptococcus pneumoniae from healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission. Pediatrics 2001, 108(4):856-865.
21. Sleeman K.L., Griffiths D., Shackley F., Diggle L., Gupta S., Maiden M.C., et al. Capsular serotype-specific attack rates and duration of carriage of Streptococcus pneumoniae in a population of children. J Infect Dis 2006, 194(5):682-688.
22. Grabowska K., Hogberg L., Penttinen P., Svensson A., Ekdahl K. Occurrence of invasive pneumococcal disease and number of excess cases due to influenza. BMC Infect Dis 2006, 6:58.
23. McCullers J.A., Rehg J.E. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis 2002, 186(3):341-350.
24. Shahangian A., Chow E.K., Tian X., Kang J.R., Ghaffari A., Liu S.Y., et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest 2009, 119(7):1910-1920.
25. van der Sluijs K.F., van Elden L.J., Nijhuis M., Schuurman R., Pater J.M., Florquin S., et al. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol 2004, 172(12):7603-7609.
26. Huber V.C., Peltola V., Iverson A.R., McCullers J.A. Contribution of vaccine-induced immunity toward either the HA or the NA component of influenza viruses limits secondary bacterial complications. J Virol 2010, 84(8):4105-4108.
27. Sun K., Ye J., Perez D.R., Metzger D.W. Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections. J Immunol 2011, 186(2):987-993.
28. McCullers J.A. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis 2004, 190(3):519-526.
29. McCullers J.A., Bartmess K.C. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis 2003, 187(6):1000-1009.
30. Song J.H., Nguyen H.H., Cuburu N., Horimoto T., Ko S.Y., Park S.H., et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci USA 2008, 105(5):1644-1649.
31. van der Sluijs K.F., Nijhuis M., Levels J.H., Florquin S., Mellor A.L., Jansen H.M., et al. Influenza-induced expression of indoleamine 2,3-dioxygenase enhances interleukin-10 production and bacterial outgrowth during secondary pneumococcal pneumonia. J Infect Dis 2006, 193(2):214-222.
32. Brandtzaeg P., Pabst R. Let's go mucosal: communication on slippery ground. Trends Immunol 2004, 25(11):570-577.
33. Briles D.E., Miyaji E., Fukuyama Y., Ferreira D.M., Fujihashi K. Elicitation of mucosal immunity by proteins of Streptococcus pneumoniae. Adv Otorhinolaryngol 2011, 72:25-27.
34. Fukuyama Y., King J.D., Kataoka K., Kobayashi R., Gilbert R.S., Oishi K., et al. Secretory-IgA antibodies play an important role in the immunity to Streptococcus pneumoniae. J Immunol 2010, 185(3):1755-1762.
35. Boyaka P.N., McGhee J.R., Czerkinsky C., Mestecky J. Mucosal vaccines: an overwiew. Mucosal immunology 2007, Elsevier/Academic Press, Amsterdam, p. 855-874. 3rd ed. J. Mestecky, J. Bienenstock, M.E. Lamm, L. mayer, J.R. McGhee, W. Strober (Eds.).
36. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004, 350(9):896-903.
37. Nagarkar D.R., Wang Q., Shim J., Zhao Y., Tsai W.C., Lukacs N.W., et al. CXCR2 is required for neutrophilic airway inflammation and hyperresponsiveness in a mouse model of human rhinovirus infection. J Immunol 2009, 183(10):6698-6707.
38. Ware L.B., Matthay M.A. The acute respiratory distress syndrome. N Engl J Med 2000, 342(18):1334-1349.
39. (hi) monocytes and neutrophils during acute viral pneumonia in mice. PLoS Pathog 2011, 7(2):e1001304.
40. Esser M.T., Marchese R.D., Kierstead L.S., Tussey L.G., Wang F., Chirmule N., et al. Memory T cells and vaccines. Vaccine 2003, 21(5-6):419-430.